News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sorrento Therapeutics, Inc. Announces the Appointment of Martina Molsbergen as Vice President, Business Development


10/27/2009 10:15:26 AM

SAN DIEGO, Oct. 27 /PRNewswire/ -- Sorrento Therapeutics, Inc. announced today that Martina Molsbergen has joined the Company as Vice President, Business Development. Ms. Molsbergen will focus her efforts on all aspects of business development, including forming alliances based on Sorrento Therapeutics' human monoclonal antibody libraries and technologies.

Dr. Antonius Schuh, Chairman and CEO of Sorrento Therapeutics, commented, "There has been a growing demand from the pharmaceutical and biotechnology industries for antibody-based technologies. Martina brings forth skill sets necessary to capture the value of our human antibody library platform. Her expertise and in-depth knowledge of our industry will be a most valuable asset to Sorrento Therapeutics as we expand our technology platform and product pipeline activities."

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company seeks to construct an antibody library containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets appropriate for antibody therapy.

For more information about Sorrento Therapeutics, Inc., visit its web site at www.sorrentotherapeutics.com.

Sorrento Therapeutics, Inc.



Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES